Dr D.Y.H Poon & Associates Medical Oncology Clinic
38 Irrawaddy Road #06-44/45
Mount Elizabeth Novena Specialist Centre
+65 6262 0672
Monday – Friday
8:30am – 5:30pm
8.30am – 1pm
Sunday & Public Holidays
Dr Donald Poon
MBBS (NUS), MMED (INT MED), MRCP (UK), FAMS (MEDICAL ONCOLOGY)
SPECIALIST IN MEDICAL ONCOLOGY
Dr Poon manages all tumour types in his main General Oncology practice. He has a special interest in the following fields:
- GERIATRIC ONCOLOGY – ELDERLY WITH CANCER
- GASTROINTESTINAL / HEPATOBILIARY / PANCREATIC TUMOURS
- NEUROENDOCRINE TUMOURS / CARCINOID
SARCOMA / MELANOMA
Dr Donald Poon is a Medical Oncologist who graduated from NUS in 1996. He underwent advanced specialty training in medical oncology at National Cancer Centre, Singapore (NCCS), and subsequently practised as a consultant in NCCS before leaving NCCS to help build up a comprehensive oncology service in Raffles Cancer Centre in Raffles Hospital in 2010.
Dr Poon was Assistant Professor in Medicine at Duke-NUS Graduate Medical School 2008 – 2010. He was also Honorary Medical Director of Singapore Cancer Society from 2007 to 2009, and founding President of the Society of Geriatric Oncology in Singapore. In recognition of his efforts in patient care, he received the Humanity Healthcare Award in 2006 and STAR Excellent Service Award in 2009.
In addition to general medical oncology, Dr Poon has keen interest in sarcoma, melanoma, stomach cancer, colorectal cancer, liver cancer, pancreatic cancer, bile duct cancer, GIST, neuroendocrine tumours/carcinoid tumours and geriatric oncology. He developed a Geriatric Oncology programme that specialises in treating elderly patients with all varieties of cancer, and was given the SingHealth HMDP training award in Geriatric Oncology in Moffitt Cancer Centre, USA in 2006.
Dr Poon has previously received a National Medical Research Council (NMRC) grant award of more than S$1 million in his research in liver cancer as a Co-Principal Investigator. His research in Geriatric Oncology was also selected for oral presentation at the prestigious 2008 American Society of Clinical Oncology Annual Meeting. He is also an active clinical investigator in multiple investigator-initiated and industry-sponsored clinical trials.
Apart from being regularly invited to be a speaker as teaching faculty in various specialty forums in the region and internationally such as the European Society of Medical Oncology (ESMO) Neuroendocrine Tumour Preceptorship Programme, his often cited research work in oncology has been extensively published in more than 40 scientific papers in high impact factor international oncology journals such as Cancer, Journal of Clinical Oncology, and Lancet Oncology.
Dr Daryl Tan
MBBS (S’pore), M Med (Int Med), MRCP (UK), FAMS
SPECIALIST IN HAEMATOLOGY
Dr Daryl Tan is a haematologist. He graduated from National University of Singapore in 1997 and obtained his membership with the Royal College of Physicians (United Kingdom) in 2002. He received his internal medicine and haematology training at the Singapore General Hospital.
In 2007, he was awarded the Singapore Government Human Manpower Development Plan (HMDP) fellowship to pursue postdoctoral training and clinical research in the field of lymphoma at Stanford University, USA. Upon his return , Dr Tan served as the clinical lead for the lymphoma and myeloma services at the Singapore General Hospital and spearheaded several clinical trials examining novel approaches in treating lymphoma and multiple myeloma.
He was Assistant Professor at the Duke-NUS Graduate Medical School and received numerous grants from the National Medical Research Council, Singapore Health Foundation and the Singapore Cancer Syndicate for his research. Dr Tan joined Raffles Hospital in 2011 to help set up a comprehensive haematology service and became the managing partner of the Raffles Cancer Centre and the Director of Research of Raffles Hospital. He integrated research with clinical practice, availing novel therapeutics for cancer patients failing standards of care.
In recognition of his commitment and dedication to patient care, he received the Singapore Health Service Quality Service Gold Award in 2011, long service awards from the Singapore General Hospital and Raffles Hospital in 2008 and 2017 respectively, and the Courage Medal during the Singapore SARS epidemic in 2003.
Being the principal investigator of more than 40 investigator-initiated and industry-sponsored clinical studies allowed him to gain early experience with state-of-the art innovations in the treatment of blood cancers. His research has led to several international presentations and more than 100 publications in high impact factor scientific journals including numerous first-authored articles in the Lancet Oncology, Blood and the Annals of Oncology. His expertise in lymphoma and multiple myeloma was recognized by the publication of two lead-author review articles on their respective treatment guidelines in Lancet Oncology in 2014. Dr Tan’s pioneering work on immunotherapy in NK/T-cell lymphoma has led to its endorsement on the American NCCN cancer treatment guidelines in 2018.
Dr Tan was elected into the International Myeloma Working Group in 2014 and also sits on the advisory panel of the International Myeloma Foundation’s Asia Myeloma Network. He is also a member of the Asia Lymphoma Study Group, the American Society of Haematology and the American Society of Clinical Oncology. As a key opinion leader, he has delivered more than 80 invited lectures on the treatment of lymphoma and multiple myeloma at international and regional conferences and serves as an advisor to many regional and international expert panels on novel drugs development.
Dr Tan is currently a board member of the Chapter of Haematologists and is appointed by the Ministry of Health as an advisor for the Residency Advisory Committee for Haematology training in Singapore. His continued affiliation with the academic hospitals allows him to contribute to post-graduate teaching, and to advise patients on participation in clinical trials for lymphoma and multiple myeloma.
Request a Call Back
Learn more about the types of cancer, screening, treatments, patient care available. Providing excellent service is our priority, make an appointment today.